by Lori Solomon The U.S. Food and Drug Administration has approved Organon’s Vtama (tapinarof) 1% cream for an additional indication — the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 years and older. ADVERTISING The cream, an aryl hydrocarbon receptor agonist, was previously approved as a topical, nonsteroidal treatment for plaque psoriasis....
Tag: <span>atopic dermatitis</span>
Post
FDA approves Nemluvio for moderate-to-severe atopic dermatitis
by Lori Solomon The U.S. Food and Drug Administration has approved Galderma’s Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older. The approval is for use in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. Nemluvio is the first approved...
Post
Nemolizumab Reassures in Long-Term Follow-Up Atopic Dermatitis Study
Liam Davenport October 21, 2024 059 Added to Email Alert AMSTERDAM — The monoclonal antibody nemolizumab offers long-term efficacy and safety, as well as quality-of-life benefits, in the management of adolescents and adults with moderate to severe atopic dermatitis (AD), revealed an interim analysis of the ARCADIA open-label extension study. The research was presented at the European Academy...
Post
Research shows dupilumab effective in treatment of children with atopic dermatitis
by National Jewish Health Credit: CC0 Public Domain Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to...
Post
Long-term upadacitinib use feasible for adolescents with atopic dermatitis
by Lori Solomon Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA Dermatology. Amy S. Paller, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues evaluated the efficacy and adverse events of upadacitinib in adolescent patients with...
Post
Atopic Dermatitis Control on Biologic Persists Over 3 Years
AMSTERDAM, Netherlands — For patients with atopic dermatitis (AD) who responded to the anti-interleukin (IL)-13 monoclonal antibody lebrikizumab in the pivotal trials, the level of response, including 90% skin clearance, has generally remained unchanged among those followed up for an additional 2 years, according to the latest data from an extension study. At the end...
Post
Dietary vitamin E may be protective against atopic dermatitis
August 30, 2024 by Lori Solomon Dietary intake of vitamin E may potentially lower the risk for atopic dermatitis, according to a study published online Aug. 9 in Skin Research & Technology. Siqing Wang, from the Beijing University of Chinese Medicine, and colleagues conducted a Mendelian randomization analysis to explore the causal relationship between dietary...
Post
FDA approves Zoryve for atopic dermatitis
JULY 12, 2024 by Lori Solomon The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics’ Zoryve (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients (ages 6 years and older). Zoryve is a once-daily, steroid-free cream that the company says will be available at the end of July....
Post
Experimental Topical Drug Shows Promise for Atopic Dermatitis, Psoriasis
Doug Brunk An experimental topical phosphodiesterase 4 (PDE4) inhibitor showed superior efficacy to vehicle in patients with mild to moderate atopic dermatitis (AD) and plaque psoriasis, results from a phase 2a study showed. PDE4 inhibitors are a promising therapeutic target for inflammatory diseases because “they can increase cyclic adenosine monophosphate levels and subsequently reduce the...
Post
New guidelines released for practitioners treating anaphylaxis and atopic dermatitis
by American College of Allergy, Asthma, and Immunology Credit: Unsplash/CC0 Public Domain Two new practice parameters from the Joint Task Force for Practice Parameters (JTFPP) offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis (AD) in pediatric and adult patients. The Joint Task Force is a partnership between the American College of...